Present preliminary clinical data from Phase II melanoma study

OncoSec will be presenting subset data from the Phase II melanoma study at the EADO conference on November 14 – 17 in Barcelona, Spain.

More news to come soon.

CEO Punit Dhillon Will Present at BIOX, Cancer Immunotherapy and IN3 Device Conferences and Participate at Burrill and Cowen Conferences

SAN DIEGO – September 20, 2012 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the following healthcare and investor conferences in upcoming weeks:

– Noble Financial BioXposition (BIOX), University of Connecticut, Stamford Campus, Stamford, CT, September 24 at 4:00 PM ET

– MD Becker Third Annual “Cancer Immunotherapy: A Long Awaited Reality” Conference, New York Academy of Medicine, New York, NY, October 4 at 9:15 AM ET

– Investment in Innovation (IN3) Medical Device 360° Summit, Intercontinental Mark Hopkins, San Francisco, CA, October 16 at 10:30 AM PT

In addition, Mr. Dhillon will attend the exclusive Burrill & Company Biotech Meeting in Laguna Beach, CA on October 7-9 and the Cowen Group 15th Annual Therapeutics Conference in New York, NY on October 10.

Following the Noble Financial and MD Becker events, a video webcast of the presentations can be viewed on OncoSec’s website at: http://oncosec.com/index.php/press-media/events-media/


Real Time Web Analytics